| 영문 | risk factor | 한글 | 위험인자 |
|---|---|---|---|
| 설명 | 국제방사선방호위원회(ICRP)가 1977년 권고에서 방사선방호의 목적으로 채택한 지수로, 단위선량(1 Sv)당 확률적 영향의 발생확률을 추정하여 나타낸 것이다. 생식선 선량에 대한 유전적영향의 발생률(4×10－3/Sv)이나 적색골수선량에 대한 백혈병 발생률(2×10－3/Sv)등 외에 뼈, 허파, 갑상샘, 젖샘, 기타 조직의 위험지수를 측정하여, 확률적 영향의 전신에 있어서 치사위험지수의 합계를 16.5×10－3/Sv로 하였다. 그후 ICRP는 1990년 권고에서 대상이 되는 조직과 장기를 추가하고, 수치 개정을 하면서 명칭도 각목적확률지수라고하였다. 이 권고에 의하면, 치사적 확률적 영향의 확률지수의 합계는, 일반인에 있어 60.0×10－3/Sv이다. |
||
| TF | free thyroxine; tactile fremitus; tail flick [reflex]; temperature factor; testicular feminization; ... |
|---|---|
| HDF | host defense factor; human diploid fibroblast |
| IHF | Industrial Health Foundation; integration host factor; International Hospital Foundation |
| DF | decapacitation factor; decontamination factor; deferoxamine; deficiency factor; defined flora [anima... |
| GRF | gastrin-releasing factor; genetically related macrophage factor; gonadotropin-releasing factor; grow... |
| host restriction-modification | A bacterial system where the bacterium is able to destroy invading DNA from a bacteriophage (virus which infects bacteria) while at the same time preventing the destruction of their own DNA. The phage DNA is cleaved by a restriction enzyme made by the bacterium, the bacterial DNA is modified (usually with methylation) so that the enzyme will not destroy it. (09 Oct 1997) |
|---|---|
| host-vector system | A combination of a bacterial host cell (i.e. A specific strain) and a virus vector (i.e. A particular bacteriophage strain) which work well together for DNA cloning. (09 Oct 1997) |
| host versus graft reaction | The normal lymphocyte mediated reactions of a host against allogeneic or xenogeneic cells acquired as a graft or otherwise, which lead to damage or/and destruction of the grafted cells. The opposite of graft-versus-host reaction. The common basis of graft rejection. (18 Nov 1997) |
| host vs graft reaction | The immune responses of a host to a graft. A specific response is graft rejection. (12 Dec 1998) |
| dead-end host | A host from which infectious agents are not transmitted to other susceptible host's. (05 Mar 2000) |
| definitive host | <epidemiology> The host in which a parasite reproduces sexually. (05 Dec 1998) |
| disease, graft-versus-host | A reaction of donated bone marrow against a patient's own tissue. Also called GVHD. (12 Dec 1998) |
| immunocompromised host | A human or animal whose immunologic mechanism is deficient because of an immunodeficiency disorder or other disease or as the result of the administration of immunosuppressive drugs or radiation. (12 Dec 1998) |
| intermediate host | <epidemiology> See vector. (05 Dec 1998) |
| transport host | An intermediate host in which no development of the parasite occurs, although its presence may be required as an essential link in the completion of the parasite's life cycle; e.g., the successive fish host's that carry the plerocercoid of Diphyllobothrium latum, the broad fish tapeworm, to larger food fish eventually eaten by man or other final host's. Synonym: transport host. (05 Mar 2000) |
| type host | <zoology> The host species with which the name-bearing type of a nominal species or subspecies was associated. (09 Jan 1998) |
| final host | <epidemiology> The host in which a parasite reproduces sexually. (05 Dec 1998) |
| animal protein factor | <biochemistry> Member of the water soluble B vitamin group, important in the proper function of the nervous system and important in proper carbohydrate, protein and fat metabolism. (27 Sep 1997) |
| protein factor | The factor (6.25) by which the nitrogen content of a protein is multiplied to give the amount of protein. (05 Mar 2000) |
| insulin-like growth-factor binding protein 1 | One of the six homologous proteins that specifically bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions. The function of this protein is not completely defined. However, several studies demonstrate that it inhibits igf binding to cell surface receptors and thereby inhibits igf-mediated mitogenic and cell metabolic actions. (proc soc exp biol med 1993;204(1):4-29) (12 Dec 1998) |